Kidney Biomarkers and Major Adverse Kidney Events in Critically Ill Patients

Alexander H. Flannery, Pharm.D., FCCM, BCCCP, BCPS Department of Pharmacy Practice and Science University of Kentucky College of Pharmacy Lexington, KY

Katherine Bosler Department of Otolaryngology – Head & Neck Surgery University of Texas Southwestern Medical Center Dallas, TX

Victor Ortiz-Soriano, MD Division of Nephrology, Bone and Mineral Metabolism, Department of Internal Medicine University of Kentucky College of Medicine Lexington, KY

Fabiola Gianella, MD Charles and Jane Pak Center for Mineral Metabolism and Clinical Research University of Texas Southwestern Medical Center Dallas, TX

Victor Prado, MD Charles and Jane Pak Center for Mineral Metabolism and Clinical Research University of Texas Southwestern Medical Center Dallas, TX

Robert D. Toto, MD Division of Nephrology, Department of Internal Medicine Charles and Jane Pak Center for Mineral Metabolism and Clinical Research University of Texas Southwestern Medical Center Dallas, TX

Orson W. Moe, MD
Division of Nephrology, Department of Internal Medicine
Charles and Jane Pak Center for Mineral Metabolism and Clinical Research
University of Texas Southwestern Medical Center
Dallas, TX

Javier A. Neyra, MD Division of Nephrology, Bone and Mineral Metabolism, Department of Internal Medicine University of Kentucky College of Medicine Lexington, KY **Correspondence:**

Javier A. Neyra, MD, MSCS **Assistant Professor** University of Kentucky Medical Center 800 Rose St, MN668 Lexington, KY 40536

Phone: 859-218-0932

Email: javier.neyra@uky.edu

Manuscript word count: 2,264

Abstract word count: 246

Support: This work was supported, in part, by the University of Texas Southwestern Medical Center O'Brien Kidney Research Core Center (P30 DK079328-06) and the National Center for

Advancing Translational Sciences (UL1TR001105). The content is solely the responsibility of

the authors and does not represent the official views of the National Institutes of Health or the

University of Texas Southwestern. JN is currently supported by an Early Career Pilot Grant from

the National Center for Advancing Translational Sciences (NCATS), National Institutes of

Health (NIH), through Grant UL1 TR001998. RT is supported by the NIH (R21- HL145424,

UH3- DK114870). OM is supported by the NIH (R01-DK091392, R01-DK092461, the George

O'Brien Kidney Research Center P30-DK-07938), the Charles and Jane Pak Center Endowed

Professor Collaborative Research Support and Innovative Research Support.

Running Heading: Kidney Biomarkers and Major Adverse Kidney Events

Keywords: acute kidney injury; biomarker; critical care; intensive care; outcome; major adverse

kidney event

Abstract:

Background: Several biomarkers of acute kidney injury (AKI) have been examined for their ability to predict AKI earlier than serum creatinine. Few studies have focused on using kidney biomarkers to better predict major adverse kidney events (MAKE), an increasingly used composite outcome in critical care nephrology research.

Methods: Single-center prospective study collecting blood and urine samples from critically ill patients with AKI KDIGO stage 2 or above, and matched controls from a single, tertiary care intensive care unit. Samples were collected at 24-48 hours after AKI diagnosis (cases) or ICU admission (controls), 5-7 days later, and 4-6 weeks following discharge for AKI patients. The primary outcome of interest was MAKE at hospital discharge.

Results: Serum/urinary neutrophil gelatinase-associated lipocalin, serum/urinary cystatin C, and urinary kidney injury molecule-1 early in the AKI or ICU course were all significantly higher in patients with MAKE compared to those not experiencing MAKE at hospital discharge. Serum cystatin C, and to a lesser extent serum NGAL, significantly improved upon a clinical prediction model of MAKE as assessed by the area under the receiver operating characteristic curve. Patients without MAKE experienced a greater decline in serum NGAL from initial measurement to second measurement than those patients experiencing MAKE.

Conclusion: Early measures of kidney biomarkers in critically ill patients are associated with MAKE. This relationship appears to be greatest with serum NGAL and cystatin C, which display additive utility to a clinical prediction model. Trending serum NGAL may also have utility in predicting MAKE.

Keywords: acute kidney injury; biomarker; critical care; intensive care; outcome; major adverse kidney event

The last decade has seen an explosion of research on biomarkers of acute kidney injury (AKI). Over 15 different biomarkers have been investigated, with a combination of markers receiving US Food and Drug Administration (FDA) approval in 2014 for detecting AKI within the ensuing 12 hours: the product of tissue inhibitor of metalloproteinase 2 TIMP-2 and insulinlike growth factor binding protein 7 [TIMP-2] x [IGFBP7].^{1,2} The primary focus of these studies was the search for a biomarker that would detect AKI sooner than serum creatinine, allowing earlier recognition to improve care.^{3,4} A secondary aim of this line of research has been to improve risk stratification and longer term prognostication with kidney biomarkers. This is particularly relevant for patients in the intensive care unit (ICU), where the incidence of AKI is high and conversations with family and decisions regarding supportive therapies such as renal replacement therapy (RRT) can be facilitated by improved prognostication of AKI that extends beyond the period of the acute illness.

Major adverse kidney events (MAKE), the composite of death, need of RRT, or worsened kidney function, is increasingly recognized as an important, patient-centered outcome for studies of AKI, particularly in critically ill patients. Previous studies of biomarkers for AKI have primarily limited evaluation of associations with MAKE out to 30 days, thus we sought to assess the relationship with AKI at further time intervals from AKI onset. Further, limited literature has been published to predict MAKE, specifically from clinical models of ICU patients, but preliminary data suggest simple models considering severity of illness provide good performance predicting MAKE out to 30 days. Accordingly, we sought to assess kidney biomarker relationships with MAKE at various time points out to one year of follow-up and test

Methods:

Study Design and Participants

This was a secondary analysis of the AKI biobank from the "Klotho and Acute Kidney Injury" (KLAKI) Study Group.⁷ In brief, this single center, prospective study enrolled adult patients ≥ 18 years old over a one year period admitted to the ICU with stage ≥ 2 AKI per Kidney Disease: Improving Global Outcomes (KDIGO) criteria and matched controls based on age, gender, and baseline estimated glomerular filtration rate (eGFR).⁸ Patients must have had a baseline eGFR ≥ 60 mL/min/1.73 m². Patients were excluded if they had end-stage kidney disease (ESKD), a kidney or any other solid organ transplant, evidence of AKI prior to ICU admission, or uroepithelial tumors.⁷

Data Collection and Laboratory Analysis

Blood and urine samples were taken from all patients at an initial time point (T1), 24-48 hours after AKI diagnosis (cases) or ICU admission (controls). A second set of samples (T2) was obtained 5-7 days following this initial collection. For AKI patients, a third set (T3) was collected 4-6 weeks following discharge if patients survived and followed up with clinic visit. Blood and urine samples were centrifuged at 1,000g at 4°C for 10 minutes, supernatant aliquoted into cryovials, and stored at -80°C until biomarker measurement. Serum neutrophil gelatinase-associated lipocalin (NGAL) and cystatin C and urinary NGAL, cystatin C, and kidney injury molecule-1 (KIM-1) were measured using Enzyme-Linked Immunosorbent Assay (ELISA) (BioPorto Diagnostics, Needham, MA; R&D Systems, Minneapolis, MN). Capillary electrophoresis was used to measure urinary creatinine and serum creatinine was obtained from

routine clinical care. Baseline demographics, comorbidities, and clinical data associated with the ICU admission were collected, including the Acute Physiology and Chronic Health Evaluation (APACHE) II and Charlson Comorbidity Index (CCI). 10, 11

Outcomes and Statistical Analysis

The primary study objective was to compare biomarker measurements between patients with and without the outcome of MAKE at the following time points: hospital discharge (DC), 90 days (90), 6 months (6 mo), and 1 year (1 yr). At the specified time point, MAKE was defined as any of the following: death, RRT dependence, or decrease in eGFR to <75% of baseline. Secondarily, we sought to assess whether biomarker measurements at time T1 improved upon a clinical prediction model for MAKE-DC. In an exploratory analysis, we examined the trajectory of the biomarkers between times T1 and T2 (the Δ change in biomarker= value at time T2 – value at time T1) in those patients with and without MAKE-DC.

Urinary biomarkers were normalized to urinary creatinine (Ucr) in reporting. Categorical data are presented as proportions and continuous data as medians with interquartile ranges or means \pm standard deviation depending on the distribution. Categorial variables were compared using a chi-square or Fisher's exact test, as appropriate. Continuous variables were compared using an independent samples t-test or Mann Whitney-U test. A logistic regression model for MAKE-DC was generated using a simple clinical prediction model with two variables, APACHE II and CCI based on the number of MAKE-DC events in the dataset. Collinearity was assessed with the use of variance inflation factors. The added value of individual biomarkers from T1 was assessed with their addition to the model with the use of the area under the receiver operating characteristic curve (AUROC). Statistical significance was considered a two-sided p

value < 0.05. Analyses were performed in Stata (Version 16.1; Stata Corp, College Station, TX) and R (R Foundation for Statistical Computing, Vienna, Austria).

Results:

The study included a total of 106 patients, 54 with AKI and 52 matched controls. Patient characteristics are shown in **Table 1**. Per the study design, AKI and controls were not different in age, sex, or baseline eGFR. A greater proportion of AKI patients were in the medical ICU compared to a greater proportion of control patients that were admitted to the surgical ICU. AKI patients tended to be more acutely ill overall, as evidenced by higher APACHE II and a greater need for vasopressors and mechanical ventilation. AKI patients also had more liver disease and a higher CCI compared to controls.

Biomarker values at time points T1, T2, and T3 are compared between AKI patients and controls in **Table 2**. Seven AKI patients were anuric and thus unable to contribute urine specimens. Death, discharge, or loss to follow up were other reasons for absence of a repeated measurement at the later time points of T2 and T3. Serum and urine biomarkers at all time points were higher, often by several orders of magnitude, in patients with AKI compared to controls, with the exception of urinary KIM-1/Ucr at time point T2. Of note, AKI patients with measurements at time point T3, several weeks following AKI, demonstrated sustained elevations in biomarkers, particularly serum NGAL and cystatin C, that were as high or higher than values in the control group at time T1.

All biomarkers assessed at time T1 were significantly more elevated in patients experiencing MAKE-DC than those not (**Table 3**). Serum NGAL and cystatin C were the only biomarkers at time T2 that were significantly higher in patients experiencing MAKE-DC compared to those not. These biomarker values at T1 and T2 between patients experiencing

MAKE-DC and those not can be visualized in **Figure 1**. Serum/urinary NGAL and serum cystatin C measurements at time T1 were significantly higher in those patients with MAKE-DC, MAKE-90, MAKE-6 mo, and MAKE-1 yr. Urinary cystatin C/Ucr and urinary KIM-1/Ucr measurements at timepoint T1 were significantly higher in MAKE patients than non-MAKE patients out to six months, but not at 1 year.

The simple clinical model for MAKE-DC including APACHE II and CCI produced an AUROC of 0.827, with both APACHE II (Odds Ratio (OR) 1.13; 95% CI 1.06-1.21) and CCI (1.41; 95% CI 1.15-1.74) independent predictors of MAKE-DC. Both serum NGAL (AUROC = 0.873) and serum cystatin C (AUROC=0.941) when independently added to the simple clinical model improved the AUROC (p= 0.019 and 0.001, respectively) as shown in **Figure 2**. None of the urinary biomarkers improved upon the simple clinical model for the prediction of MAKE-DC.

In the exploratory analysis of biomarker trajectory from timepoint T1 to T2, only the change in serum NGAL (Δ NGAL) was significantly different in those patients experiencing MAKE-DC compared to those not. Those patients experiencing greater decreases in serum NGAL from time point T1 to T2 were less likely to experience MAKE-DC compared to those not (p=0.013) (**Table 4**). To account for baseline serum NGAL at time T1, both T1 and T2 serum NGAL values were assessed in a logistic regression model for MAKE-DC and the serum NGAL value at T2 remained significantly associated with MAKE-DC (OR 1.006; 95% CI 1.001-1.012).

Discussion:

In this study of critically ill patients, serum and urinary biomarkers of AKI early in the course of AKI or absence of AKI in the ICU stay were significantly higher in those patients experiencing MAKE at several time periods, including hospital discharge, 90 days, 6 months,

and 1 year. Of these, serum NGAL and cystatin C appeared to have the most utility when added to a simple clinical prediction model consisting of APACHE II and CCI. We also present evidence suggesting that trending these biomarkers in AKI may carry prognostic value. Overall, for the purpose of predicting MAKE events and trending biomarkers, serum NGAL and cystatin C appeared to perform strongest from the population in our study.

AKI biomarker panels, including multiple markers such as tubular injury and renal stress, have been theorized to have important implications for personalized medicine of AKI patients and the potential to improve prognostic, diagnostic, and therapeutic tools. ¹² Although not explored in our analysis, the combination of these biomarker panels has been shown in some settings to improve the predictive capability for AKI, particularly in the post-cardiac surgery setting. 13-16 The value of biomarker trajectory modeling in critical illness is gaining traction, and although AKI subphenotypes based on serum creatinine have been examined, the value of repeated kidney biomarker assessments remains an area of active investigation. ¹⁷ The repeated assessment of kidney biomarkers not only applies to the acute care setting, but to outpatient follow up as well. Follow up with a nephrologist after severe AKI has been associated with reduced all-cause mortality, and these biomarker assessments in the AKI recovery period may help to guide prognosis and therapy to reduce the development of chronic kidney disease post-AKI. Our sample size from the post-AKI visit at 4-6 weeks following AKI was unfortunately not large enough to evaluate this utility further. We did note that serum NGAL and cystatin C values at the T3 time point in AKI patients tended to be numerically higher than values obtained from the control group at T1 and T2 and are worthy of additional study in the post-AKI recovery setting.

This is certainly not the first study to investigate serum NGAL or cystatin C. However, the vast majority of the literature on these biomarkers is related to the prediction of AKI, for which they have generally not performed as well as anticipated. Given the increasing use of MAKE-DC or MAKE-30 as a primary outcome of clinical trials of AKI, particularly in the ICU setting, the ability to apply a biomarker to clinical prediction has great benefit in terms of prognostic enrichment and risk stratification in clinical trials. The association of biomarker levels with important patient-centered outcomes, including death, need of RRT, or reduced eGFR, out to one year is also important in the consideration of family discussions, discharge planning, and goals of care in the ICU setting.

A major strength of our study is the prospective design and follow-up of biomarkers and clinical outcomes at repeated time intervals, including out to one year. Although biomarkers are generally recognized to respond differently depending on the specific kidney insult (i.e. sepsis, ischemia, etc), our study encompassed medical, surgical, and cardiac ICUs which increases its generalizability to several different areas of practice and research. While each type of kidney insult may produce its own specific pattern of kidney biomarker expression, often the kidney injury in the ICU is multifactorial thus biomarkers applicable to a wide variety of clinical settings are desirable. We used well-established criteria for the diagnosis of AKI and the outcome of interest (MAKE).^{5,8}

Our findings are not without their noted limitations. First, the cohort was from a single center and relatively small sample size. Due to death or loss to follow-up, missing data were more prevalent than preferred for both biomarker measurement at time T2 or T3 as well as MAKE events after hospital discharge, which increases the chance of bias when analyzed using complete-case analysis as we have done. These factors limited the number of covariates we

could include in the clinical prediction model, and the possibility exists that a more detailed clinical prediction model for MAKE events may not benefit from the addition of biomarker measurements. While we noted the broad population of the cohort as a strength, it could potentially represent a limitation if it diluted the effect of any one biomarker in a specific patient population, such as sepsis. Finally, we only included AKI stage 2 and greater without chronic kidney disease at baseline, thus patients with AKI stage 1 or chronic kidney disease may not be adequately addressed in this study. Future research offers the opportunity to evaluate the predictive performance of these biomarkers, particularly serum NGAL and cystatin C, and more specifically their trajectories, in larger numbers of critically ill patients with AKI to further investigate the dose-response relationship and trajectory relationships between biomarker

Conclusion:

elevation and pertinent clinical outcomes.

Early measurement of kidney biomarkers in critically ill patients associates with MAKE at hospital discharge. This relationship appears to be greatest with serum NGAL and cystatin C, which display additive performance to a simple clinical prediction model. Trending serum NGAL may also help predict MAKE at discharge.

Disclosure: The authors have disclosed that they do not have any potential conflicts of interest.

Acknowledgments: N/A

- 1. Griffin BR, Gist KM, Faubel S. Current Status of Novel Biomarkers for the Diagnosis of Acute Kidney Injury: A Historical Perspective. *J Intensive Care Med* 2020; 35(5): 415-424.
- 2. Vijayan A, Faubel S, Askenazi DJ, et al. Clinical Use of the Urine Biomarker [TIMP-2] x [IGFBP7] for Acute Kidney Injury Risk Assessment. *Am J Kidney Dis* 2016; 68(1): 19-28.
- 3. Kashani K, Al-Khafaji A, Ardiles T, et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. *Crit Care* 2013; 17(1): R25.
- 4. Parikh CR, Coca SG, Thiessen-Philbrook H, et al. Postoperative biomarkers predict acute kidney injury and poor outcomes after adult cardiac surgery. *J Am Soc Nephrol* 2011; 22(9): 1748-1757.
- 5. Billings FTt, Shaw AD. Clinical trial endpoints in acute kidney injury. *Nephron Clin Pract* 2014; 127(1-4): 89-93.
- 6. McKown AC, Wang L, Wanderer JP, et al. Predicting Major Adverse Kidney Events among Critically III Adults Using the Electronic Health Record. *J Med Syst* 2017; 41(10): 156.
- 7. Neyra JA, Li X, Mescia F, et al. Urine Klotho Is Lower in Critically III Patients With Versus Without Acute Kidney Injury and Associates With Major Adverse Kidney Events. *Crit Care Explor* 2019 Jun 26;1(6):e0016.
- 8. Kidney Disease: Improving GlobalOutcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guidelinefor Acute Kidney Injury.Kidney inter., Suppl.2012;2: 1–138.
- 9. Zinellu A, Caria MA, Tavera C, et al. Plasma creatinine and creatine quantification by capillary electrophoresis diode array detector. *Anal Biochem* 2005; 342(2): 186-193.
- 10. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis* 1987; 40(5): 373-383.
- 11. Knaus WA, Draper EA, Wagner DP, et al. APACHE II: a severity of disease classification system. *Crit Care Med* 1985; 13(10): 818-829.
- 12. Basu RK. Dynamic Biomarker Assessment: A Diagnostic Paradigm to Match the AKI Syndrome. *Front Pediatr* 2019; 7: 535.
- 13. Arthur JM, Hill EG, Alge JL, et al. Evaluation of 32 urine biomarkers to predict the progression of acute kidney injury after cardiac surgery. *Kidney Int* 2014; 85(2): 431-438.

- 15. Meisner A, Kerr KF, Thiessen-Philbrook H, et al. Development of biomarker combinations for postoperative acute kidney injury via Bayesian model selection in a multicenter cohort study. *Biomark Res* 2018; 6: 3.
- 16. Neyra JA, Hu MC, Minhajuddin A, et al. Kidney Tubular Damage and Functional Biomarkers in Acute Kidney Injury Following Cardiac Surgery. *Kidney Int Rep* 2019; 4(8): 1131-1142.
- 17. Bhatraju PK, Mukherjee P, Robinson-Cohen C, et al. Acute kidney injury subphenotypes based on creatinine trajectory identifies patients at increased risk of death. *Crit Care* 2016; 20(1): 372.
- 18. Harel Z, Wald R, Bargman JM, et al. Nephrologist follow-up improves all-cause mortality of severe acute kidney injury survivors. *Kidney Int* 2013; 83(5): 901-908.

Characteristics	AKI (n=54)	No AKI (n=52)	p-value
Age (years)	55.8 ± 16.7	58.0 ± 14.5	0.471
Sex (% male)	31(57.4%)	29 (55.8%)	0.865
Race	White-34(63.0%)	White-40(76.9%)	0.183
	Black-12(22.2%)	Black-5(9.6%)	
	Other-8(14.8%)	Other-7(13.5%)	
ICU Type	SICU-9(16.7%)	SICU-18(34.6%)	0.001
	MICU-26(48.2%)	MICU-6(11.5%)	
	CCU-10(18.5%)	CCU-15(28.9%)	
	Other ICU-		
	9(16.7%)	Other ICU-13(25%)	
Diabetes (%)	17(31.5%)	10(19.2%)	0.148
Hypertension (%)	27(50.0%)	29(55.8%)	0.552
Heart Failure (%)	15(27.8%)	17(32.7%)	0.582
Liver Disease (%)	18(33.3%)	6(11.5%)	0.007
Cancer (%)	23(42.6%)	23(45.1%)	0.796
Baseline Serum Creatinine (mg/dl)	0.86 ± 0.26	0.82 ± 0.20	0.323
Baseline eGFR (ml/min)	88 (69.5-104)	92 (78.3-103)	0.399
APACHE II	20 (16-26)	12 (9-19)	< 0.001
Number Pressors/inotropes	1.5 (0-3)	0 (0-1)	0.001
Mechanical Ventilation (%)	34 (63.0%)	20 (38.5%)	0.012
Charlson Comorbidity Index	4 (2.8-7)	2 (2-4)	< 0.001

Biomarker	n	AKI (n=54)	n	No AKI (n=52)	p-value
Serum NGAL Time 1 (ng/ml)	54	487 (342-1317)	52	163 (115-213)	< 0.001
Serum NGAL Time 2 (ng/ml)	29	441 (290-705)	7	153 (118-185)	0.001
Serum NGAL Time 3 (ng/ml)	22	233 (178-360)			
Urinary NGAL/Ucr Time 1(ng/ml)	47	1305 (304-6068)	52	32 (9-85)	< 0.001
Urinary NGAL/Ucr Time 2 (ng/ml)	26	791 (301-2436)	7	62 (29-82)	0.001
Urinary NGAL/Ucr Time 3 (ng/ml)	20	72 (30-498)			
Serum Cystatin C Time 1 (ng/ml)	54	2122 (1189-2978)	52	712 (576-842)	< 0.001
Serum Cystatin C Time 2 (ng/ml)	29	1506 (1111-2258)	7	833 (623-974)	0.001
Serum Cystatin C Time 3 (ng/ml)	21	1299 (908-2387)			
Urinary Cystatin C/Ucr Time 1 (ng/ml)	47	785 (125-1561)	52	48 (9-166)	< 0.001
Urinary Cystatin C/Ucr Time 2 (ng/ml)	26	652 (182-1462)	7	63 (17-128)	0.003
Urinary Cystatin C/Ucr Time 3 (ng/ml)	19	68 (44-325)			
Urinary KIM-1/Ucr Time 1 (ng/ml)	47	5.7 (3.3-13.9)	52	2.3 (1.2-4.4)	< 0.001
Urinary KIM-1/Ucr Time 2 (ng/ml)	47	5.2 (3.1-8.1)	7	4.1 (0.9-5.4)	0.308
Urinary KIM-1/Ucr Time 3 (ng/ml)	20	2.3 (1.7-4.3)			

Time 1: 24-48 hours after AKI diagnosis (cases) or ICU admission (controls)

Time 2: 5-7 days following Time 1 collection

Time 3: 4-6 weeks following discharge if patient survived and followed up with clinic visit

Biomarker	MAKE at Discharge (n=49)	No MAKE at Discharge (n=57)	p- value	MAKE at 90 Days (n=47)	No MAKE at 90 Days (n=35)	p- value
Serum NGAL Time 1 (ng/ml)	485 (340-1190)	175 (117-235)	< 0.001	483 (244-1307)	189 (119-304)	< 0.001
Serum NGAL Time 2 (ng/ml)	452 (277-952) (n=23)	163 (120-439) (n=13)	0.011	441 (238-804) (n=21)	157 (133-437) (n=7)	0.062
Serum NGAL Time 3 (ng/ml)				237 (200-886) (n=12)	238 (106-516) (n=5)	0.574
Urinary NGAL/Ucr Time 1 (ng/ml)	1037 (283-6085) (n=42)	38 (10-103)	< 0.001	850 (140-3649) (n=40)	34 (10-99)	< 0.001
Urinary NGAL/Ucr Time 2 (ng/ml)	553 (82-2488) (n=20)	109 (49-1534) (n=13)	0.316	553 (75-1322) (n=18)	109 (35-2496) (n=7)	0.790
Urinary NGAL/Ucr Time 3 (ng/ml)				259 (40-891) (n=10)	30 (15-561) (n=5)	0.165
Serum Cystatin C Time 1 (ng/ml)	2283 (1153-3038)	716 (579-923)	< 0.001	2018 (837-3002)	713 (574-1024)	< 0.001
Serum Cystatin C Time 2 (ng/ml)	1565 (1117-2464) (n=23)	974 (679-1424) (n=13)	0.006	1369 (1100-2554) (n=21)	962 (667-1403) (n=7)	0.036
Serum Cystatin C Time 3 (ng/ml)				1668 (1201-2595) (n=12)	1445 (813-3124) (n=4)	0.599
Urinary Cystatin C/Ucr Time 1 (ng/ml)	611 (122-1601) (n=42)	56 (14-620)	< 0.001	339 (48-1529) (n=40)	68 (17-837)	0.047
Urinary Cystatin C/Ucr Time 2 (ng/ml)	593 (41-1616) (n=20)	200 (92-726) (n=13)	0.434	370 (75-1462) (n=18)	147 (62-776) (n=7)	0.574
Urinary Cystatin C/Ucr Time 3 (ng/ml)				69 (46-820) (n=9)	116 (55-319) (n=5)	0.947
Urinary KIM-1/Ucr Time 1 (ng/ml)	5.6 (3.0-13.4) (n=42)	2.4 (1.2-6.1)	< 0.001	5.2 (2.5-13.3) (n=40)	2.3 (1.4-6.1)	0.014
Urinary KIM-1/Ucr Time 2 (ng/ml)	5.2 (3.0-7.9) (n=20)	4.1 (2.2-7.5) (n=13)	0.650	4.6 (2.8-7.7) (n=18)	5.2 (1.2-6.8) (n=7)	0.701
Urinary KIM-1/Ucr Time 3 (ng/ml)				2.4 (1.8-4.9) (n=10)	3 (1.9-4.3) (n=5)	0.953
	371777					
Biomarker	MAKE at 6 months (n=45)	No MAKE at 6 months (n=34)	p- value	MAKE at 1 year (n=48)	No MAKE at 1 year (n=27)	p- value
				MAKE at 1 year	No MAKE at 1 year	p-
Biomarker	(n=45)	months (n=34)	value	MAKE at 1 year (n=48)	No MAKE at 1 year (n=27)	p- value
Biomarker Serum NGAL Time 1 (ng/ml)	(n=45) 474 (229-1203)	months (n=34) 193 (129-312)	value <0.001	MAKE at 1 year (n=48) 426 (188-927)	No MAKE at 1 year (n=27) 192 (133-279)	p- value
Biomarker Serum NGAL Time 1 (ng/ml) Serum NGAL Time 2 (ng/ml)	(n=45) 474 (229-1203) 452 (272-1018) (n=17)	months (n=34) 193 (129-312) 158 (114-304) (n=8)	value <0.001 0.011	MAKE at 1 year (n=48) 426 (188-927) 321 (168-575) (n=20)	No MAKE at 1 year (n=27) 192 (133-279) 153 (133-336) (n=3)	p- value 0 0.31
Biomarker Serum NGAL Time 1 (ng/ml) Serum NGAL Time 2 (ng/ml) Serum NGAL Time 3 (ng/ml)	(n=45) 474 (229-1203) 452 (272-1018) (n=17) 328 (226-1277) (n=9)	months (n=34) 193 (129-312) 158 (114-304) (n=8) 150 (108-238) (n=7)	value <0.001 0.011 0.023	MAKE at 1 year (n=48) 426 (188-927) 321 (168-575) (n=20) 226 (177-1158) (n=10)	No MAKE at 1 year (n=27) 192 (133-279) 153 (133-336) (n=3) 213 (136-306) (n=4)	p- value 0 0.31 0.64
Biomarker Serum NGAL Time 1 (ng/ml) Serum NGAL Time 2 (ng/ml) Serum NGAL Time 3 (ng/ml) Urinary NGAL/Ucr Time 1 (ng/ml)	(n=45) 474 (229-1203) 452 (272-1018) (n=17) 328 (226-1277) (n=9) 510 (107-3277) (n=39)	months (n=34) 193 (129-312) 158 (114-304) (n=8) 150 (108-238) (n=7) 33 (9-150) (n=33)	value <0.001 0.011 0.023 <0.001	MAKE at 1 year (n=48) 426 (188-927) 321 (168-575) (n=20) 226 (177-1158) (n=10) 510 (92-3079) (n=41)	No MAKE at 1 year (n=27) 192 (133-279) 153 (133-336) (n=3) 213 (136-306) (n=4) 33 (10-61) (n=27)	p- value 0 0.31 0.64 <0.001
Biomarker Serum NGAL Time 1 (ng/ml) Serum NGAL Time 2 (ng/ml) Serum NGAL Time 3 (ng/ml) Urinary NGAL/Ucr Time 1 (ng/ml) Urinary NGAL/Ucr Time 2 (ng/ml)	(n=45) 474 (229-1203) 452 (272-1018) (n=17) 328 (226-1277) (n=9) 510 (107-3277) (n=39) 494 (66-2009) (n=14)	months (n=34) 193 (129-312) 158 (114-304) (n=8) 150 (108-238) (n=7) 33 (9-150) (n=33) 343 (46-1126) (n=8)	value<0.0010.0110.023<0.0010.664	MAKE at 1 year (n=48) 426 (188-927) 321 (168-575) (n=20) 226 (177-1158) (n=10) 510 (92-3079) (n=41) 459 (62-1832) (n=17)	No MAKE at 1 year (n=27) 192 (133-279) 153 (133-336) (n=3) 213 (136-306) (n=4) 33 (10-61) (n=27) 109 (35-1173) (n=3)	p-value 0 0.31 0.64 <0.001 0.69
Biomarker Serum NGAL Time 1 (ng/ml) Serum NGAL Time 2 (ng/ml) Serum NGAL Time 3 (ng/ml) Urinary NGAL/Ucr Time 1 (ng/ml) Urinary NGAL/Ucr Time 2 (ng/ml) Urinary NGAL/Ucr Time 3 (ng/ml)	(n=45) 474 (229-1203) 452 (272-1018) (n=17) 328 (226-1277) (n=9) 510 (107-3277) (n=39) 494 (66-2009) (n=14) 416 (23-904) (n=7)	months (n=34) 193 (129-312) 158 (114-304) (n=8) 150 (108-238) (n=7) 33 (9-150) (n=33) 343 (46-1126) (n=8) 42 (19-70) (n=7)	value<0.0010.0110.023<0.0010.6640.209	MAKE at 1 year (n=48) 426 (188-927) 321 (168-575) (n=20) 226 (177-1158) (n=10) 510 (92-3079) (n=41) 459 (62-1832) (n=17) 259 (34-900) (n=8)	No MAKE at 1 year (n=27) 192 (133-279) 153 (133-336) (n=3) 213 (136-306) (n=4) 33 (10-61) (n=27) 109 (35-1173) (n=3) 43 (14-167) (n=4)	p-value 0 0.31 0.64 <0.001 0.69 0.15
Biomarker Serum NGAL Time 1 (ng/ml) Serum NGAL Time 2 (ng/ml) Serum NGAL Time 3 (ng/ml) Urinary NGAL/Ucr Time 1 (ng/ml) Urinary NGAL/Ucr Time 2 (ng/ml) Urinary NGAL/Ucr Time 3 (ng/ml) Serum Cystatin C Time 1 (ng/ml)	(n=45) 474 (229-1203) 452 (272-1018) (n=17) 328 (226-1277) (n=9) 510 (107-3277) (n=39) 494 (66-2009) (n=14) 416 (23-904) (n=7) 2018 (830-3038)	months (n=34) 193 (129-312) 158 (114-304) (n=8) 150 (108-238) (n=7) 33 (9-150) (n=33) 343 (46-1126) (n=8) 42 (19-70) (n=7) 710 (571-999)	value <0.001 0.011 0.023 <0.001 0.664 0.209 <0.001	MAKE at 1 year (n=48) 426 (188-927) 321 (168-575) (n=20) 226 (177-1158) (n=10) 510 (92-3079) (n=41) 459 (62-1832) (n=17) 259 (34-900) (n=8) 1551 (801-2804)	No MAKE at 1 year (n=27) 192 (133-279) 153 (133-336) (n=3) 213 (136-306) (n=4) 33 (10-61) (n=27) 109 (35-1173) (n=3) 43 (14-167) (n=4) 713 (560-989)	p-value 0 0.31 0.64 <0.001 0.69 0.15 <0.001
Biomarker Serum NGAL Time 1 (ng/ml) Serum NGAL Time 2 (ng/ml) Serum NGAL Time 3 (ng/ml) Urinary NGAL/Ucr Time 1 (ng/ml) Urinary NGAL/Ucr Time 2 (ng/ml) Urinary NGAL/Ucr Time 3 (ng/ml) Serum Cystatin C Time 1 (ng/ml) Serum Cystatin C Time 2 (ng/ml)	(n=45) 474 (229-1203) 452 (272-1018) (n=17) 328 (226-1277) (n=9) 510 (107-3277) (n=39) 494 (66-2009) (n=14) 416 (23-904) (n=7) 2018 (830-3038) 1506 (1042-2677) (n=17)	months (n=34) 193 (129-312) 158 (114-304) (n=8) 150 (108-238) (n=7) 33 (9-150) (n=33) 343 (46-1126) (n=8) 42 (19-70) (n=7) 710 (571-999) 1035 (709-1340) (n=8)	value <0.001 0.011 0.023 <0.001 0.664 0.209 <0.001 0.043	MAKE at 1 year (n=48) 426 (188-927) 321 (168-575) (n=20) 226 (177-1158) (n=10) 510 (92-3079) (n=41) 459 (62-1832) (n=17) 259 (34-900) (n=8) 1551 (801-2804) 1358 (935-2598) (n=20)	No MAKE at 1 year (n=27) 192 (133-279) 153 (133-336) (n=3) 213 (136-306) (n=4) 33 (10-61) (n=27) 109 (35-1173) (n=3) 43 (14-167) (n=4) 713 (560-989) 974 (833-1318) (n=3)	P-value 0 0.31 0.64 <0.001 0.69 0.15 <0.001 0.31
Biomarker Serum NGAL Time 1 (ng/ml) Serum NGAL Time 2 (ng/ml) Serum NGAL Time 3 (ng/ml) Urinary NGAL/Ucr Time 1 (ng/ml) Urinary NGAL/Ucr Time 2 (ng/ml) Urinary NGAL/Ucr Time 1 (ng/ml) Serum Cystatin C Time 1 (ng/ml) Serum Cystatin C Time 2 (ng/ml)	(n=45) 474 (229-1203) 452 (272-1018) (n=17) 328 (226-1277) (n=9) 510 (107-3277) (n=39) 494 (66-2009) (n=14) 416 (23-904) (n=7) 2018 (830-3038) 1506 (1042-2677) (n=17) 2380 (1088-2708) (n=9)	months (n=34) 193 (129-312) 158 (114-304) (n=8) 150 (108-238) (n=7) 33 (9-150) (n=33) 343 (46-1126) (n=8) 42 (19-70) (n=7) 710 (571-999) 1035 (709-1340) (n=8) 1205 (955-1479) (n=6)	value <0.001 0.011 0.023 <0.001 0.664 0.209 <0.001 0.043 0.088	MAKE at 1 year (n=48) 426 (188-927) 321 (168-575) (n=20) 226 (177-1158) (n=10) 510 (92-3079) (n=41) 459 (62-1832) (n=17) 259 (34-900) (n=8) 1551 (801-2804) 1358 (935-2598) (n=20) 2206 (1097-2685) (n=10)	No MAKE at 1 year (n=27) 192 (133-279) 153 (133-336) (n=3) 213 (136-306) (n=4) 33 (10-61) (n=27) 109 (35-1173) (n=3) 43 (14-167) (n=4) 713 (560-989) 974 (833-1318) (n=3) 940 (810-1766) (n=4)	P-value 0 0.31 0.64 <0.001 0.69 0.15 <0.001 0.31 0.11
Biomarker Serum NGAL Time 1 (ng/ml) Serum NGAL Time 2 (ng/ml) Serum NGAL Time 3 (ng/ml) Urinary NGAL/Ucr Time 1 (ng/ml) Urinary NGAL/Ucr Time 2 (ng/ml) Urinary NGAL/Ucr Time 3 (ng/ml) Serum Cystatin C Time 1 (ng/ml) Serum Cystatin C Time 2 (ng/ml) Serum Cystatin C Time 3 (ng/ml) Urinary Cystatin C Time 1 (ng/ml)	(n=45) 474 (229-1203) 452 (272-1018) (n=17) 328 (226-1277) (n=9) 510 (107-3277) (n=39) 494 (66-2009) (n=14) 416 (23-904) (n=7) 2018 (830-3038) 1506 (1042-2677) (n=17) 2380 (1088-2708) (n=9) 398 (48-1561) (n=39)	months (n=34) 193 (129-312) 158 (114-304) (n=8) 150 (108-238) (n=7) 33 (9-150) (n=33) 343 (46-1126) (n=8) 42 (19-70) (n=7) 710 (571-999) 1035 (709-1340) (n=8) 1205 (955-1479) (n=6) 57 (13-650) (n=33)	value <0.001 0.011 0.023 <0.001 0.664 0.209 <0.001 0.043 0.088 0.036	MAKE at 1 year (n=48) 426 (188-927) 321 (168-575) (n=20) 226 (177-1158) (n=10) 510 (92-3079) (n=41) 459 (62-1832) (n=17) 259 (34-900) (n=8) 1551 (801-2804) 1358 (935-2598) (n=20) 2206 (1097-2685) (n=10) 280 (27-1299) (n=41)	No MAKE at 1 year (n=27) 192 (133-279) 153 (133-336) (n=3) 213 (136-306) (n=4) 33 (10-61) (n=27) 109 (35-1173) (n=3) 43 (14-167) (n=4) 713 (560-989) 974 (833-1318) (n=3) 940 (810-1766) (n=4) 53 (11-643)	P-value 0 0.31 0.64 <0.001 0.69 0.15 <0.001 0.31 0.11 0.11
Biomarker Serum NGAL Time 1 (ng/ml) Serum NGAL Time 2 (ng/ml) Serum NGAL Time 3 (ng/ml) Urinary NGAL/Ucr Time 1 (ng/ml) Urinary NGAL/Ucr Time 2 (ng/ml) Urinary NGAL/Ucr Time 3 (ng/ml) Serum Cystatin C Time 1 (ng/ml) Serum Cystatin C Time 2 (ng/ml) Urinary Cystatin C Time 3 (ng/ml) Urinary Cystatin C/Ucr Time 1 (ng/ml) Urinary Cystatin C/Ucr Time 2 (ng/ml)	(n=45) 474 (229-1203) 452 (272-1018) (n=17) 328 (226-1277) (n=9) 510 (107-3277) (n=39) 494 (66-2009) (n=14) 416 (23-904) (n=7) 2018 (830-3038) 1506 (1042-2677) (n=17) 2380 (1088-2708) (n=9) 398 (48-1561) (n=39) 503 (23-1462) (n=14)	months (n=34) 193 (129-312) 158 (114-304) (n=8) 150 (108-238) (n=7) 33 (9-150) (n=33) 343 (46-1126) (n=8) 42 (19-70) (n=7) 710 (571-999) 1035 (709-1340) (n=8) 1205 (955-1479) (n=6) 57 (13-650) (n=33) 174 (79-568) (n=8)	value <0.001 0.011 0.023 <0.001 0.664 0.209 <0.001 0.043 0.088 0.036 0.764	MAKE at 1 year (n=48) 426 (188-927) 321 (168-575) (n=20) 226 (177-1158) (n=10) 510 (92-3079) (n=41) 459 (62-1832) (n=17) 259 (34-900) (n=8) 1551 (801-2804) 1358 (935-2598) (n=20) 2206 (1097-2685) (n=10) 280 (27-1299) (n=41) 247 (23-782) (n=17)	No MAKE at 1 year (n=27) 192 (133-279) 153 (133-336) (n=3) 213 (136-306) (n=4) 33 (10-61) (n=27) 109 (35-1173) (n=3) 43 (14-167) (n=4) 713 (560-989) 974 (833-1318) (n=3) 940 (810-1766) (n=4) 53 (11-643) 147 (63-1794) (n=3)	P-value 0 0.31 0.64 <0.001 0.69 0.15 <0.001 0.31 0.11 0.11 0.84
Biomarker Serum NGAL Time 1 (ng/ml) Serum NGAL Time 2 (ng/ml) Serum NGAL Time 3 (ng/ml) Urinary NGAL/Ucr Time 1 (ng/ml) Urinary NGAL/Ucr Time 2 (ng/ml) Urinary NGAL/Ucr Time 3 (ng/ml) Serum Cystatin C Time 1 (ng/ml) Serum Cystatin C Time 3 (ng/ml) Urinary Cystatin C/Ucr Time 1 (ng/ml) Urinary Cystatin C/Ucr Time 2 (ng/ml) Urinary Cystatin C/Ucr Time 2 (ng/ml) Urinary Cystatin C/Ucr Time 3 (ng/ml)	(n=45) 474 (229-1203) 452 (272-1018) (n=17) 328 (226-1277) (n=9) 510 (107-3277) (n=39) 494 (66-2009) (n=14) 416 (23-904) (n=7) 2018 (830-3038) 1506 (1042-2677) (n=17) 2380 (1088-2708) (n=9) 398 (48-1561) (n=39) 503 (23-1462) (n=14) 437 (49-1477) (n=6)	months (n=34) 193 (129-312) 158 (114-304) (n=8) 150 (108-238) (n=7) 33 (9-150) (n=33) 343 (46-1126) (n=8) 42 (19-70) (n=7) 710 (571-999) 1035 (709-1340) (n=8) 1205 (955-1479) (n=6) 57 (13-650) (n=33) 174 (79-568) (n=8) 68 (49-116) (n=7)	value <0.001 0.011 0.023 <0.001 0.664 0.209 <0.001 0.043 0.088 0.036 0.764 0.181	MAKE at 1 year (n=48) 426 (188-927) 321 (168-575) (n=20) 226 (177-1158) (n=10) 510 (92-3079) (n=41) 459 (62-1832) (n=17) 259 (34-900) (n=8) 1551 (801-2804) 1358 (935-2598) (n=20) 2206 (1097-2685) (n=10) 280 (27-1299) (n=41) 247 (23-782) (n=17) 317 (69-1084) (n=7)	No MAKE at 1 year (n=27) 192 (133-279) 153 (133-336) (n=3) 213 (136-306) (n=4) 33 (10-61) (n=27) 109 (35-1173) (n=3) 43 (14-167) (n=4) 713 (560-989) 974 (833-1318) (n=3) 940 (810-1766) (n=4) 53 (11-643) 147 (63-1794) (n=3) 52 (49-56) (n=4)	P-value 0 0.31 0.64 <0.001 0.69 0.15 <0.001 0.31 0.11 0.11 0.84 0.07

Δ <u>Biomarker</u>	MAKE at Hospital Discharge (n=49)	No MAKE at Hospital Discharge (n=57)	p-value
Δ Serum NGAL (ng/ml)	12 (-143 to 58) (n=23)	-84 (-363 to -41) (n=13)	0.013
Δ Urinary NGAL (ng/ml)	-41 (-2491 to 144) (n=19)	-20 (-869 to 80) (n=13)	0.924
Δ Serum Cystatin C (ng/ml)	-82 (-1121 to 734) (n=23)	-87 (-232 to 142) (n=13)	0.681
Δ Urinary Cystatin C (ng/ml)	-112 (-545 to 552) (n=19)	18 (-547 to 105) (n=13)	0.893
Δ Urinary KIM-1 (ng/ml)	0 (-6 to 2) (n=19)	-1 (-8.5 to 0) (n=13)	0.185

 $[\]Delta$ = Value at 5-7 days (Time 2) minus Value at 24-48 hours (Time 1)




Figure 1. Kidney Biomarker Trends from Time 1 (24-48 hours) to Time 2 (5-7 Days)




Figure 2. Receiver operating characteristic curves for MAKE-Discharge